Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Business
Chris Markoch

SHOCKING: Why abbvie and johnson johnson could outperform pfizer | Mind Blowing Facts

Pfizer Inc. (NYSE: PFE) made a strong move higher after it became the first drug manufacturer to sign on as part of the TrumpRx platform. PFE stock is up nearly 14% since its closing price of around $23.61 on Sept. 25.

This is welcome news to long-term holders who have endured a significant dip in the stock since its vaccine-fueled surge in 2021. PFE stock trades at an attractive multiple of around 9x forward earnings and is a steady dividend payer with a dividend yielding 6.4%.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.